A time-resolved fluorescence resonance energy transfer-based HTS assay and a surface plasmon resonance-based binding assay for heat shock protein 90 inhibitors.

Heat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone required for the stability and function of a number of client proteins, many of which are involved in cancer development. The natural products geldanamycin (GM) and radicicol (RD) are known inhibitors of Hsp90, and their derivatives are being developed for the treatment of various cancers. To identify novel Hsp90 inhibitors, a highly robust time-resolved fluorescence resonance energy transfer (TR-FRET)-based HTS assay that measures the binding of biotinylated geldanamycin (biotin-GM) to the His-tagged human Hsp90 N-terminal ATP-binding domain (Hsp90N) was developed. This assay was optimized in 1536-well plates and was used as the primary assay to screen 10(6) compounds. Identified "hits" were then confirmed in a scintillation proximity assay (SPA) and a DEAE membrane-based assay for [(3)H]AAG binding to Hsp90. In addition, a surface plasmon resonance (SPR) assay that measures the direct interaction of Hsp90 with its inhibitors was developed and used to further characterize the identified inhibitors. Several potent and reversible inhibitors of human Hsp90 with K(d) values measured in the high nanomolar range were identified.

[1]  H. Scher,et al.  Hsp90 as a therapeutic target in prostate cancer. , 2003, Seminars in oncology.

[2]  Neal Rosen,et al.  Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent , 1997, Cell.

[3]  L. Neckers,et al.  KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. , 1999, Cancer research.

[4]  S. Jackson,et al.  Stimulation of the weak ATPase activity of human hsp90 by a client protein. , 2002, Journal of molecular biology.

[5]  N. Rosen,et al.  Synthesis of novel fluorescent probes for the molecular chaperone Hsp90. , 2003, Bioorganic & medicinal chemistry letters.

[6]  L. Pearl,et al.  Identification and Structural Characterization of the ATP/ADP-Binding Site in the Hsp90 Molecular Chaperone , 1997, Cell.

[7]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[8]  Andreas Schirmer,et al.  Filter binding assay for the geldanamycin-heat shock protein 90 interaction. , 2003, Analytical biochemistry.

[9]  T G Myers,et al.  DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. , 1999, Journal of the National Cancer Institute.

[10]  A. Pope.  Introduction LANCE™ vs. HTRF® Technologies (or Vice Versa) , 1999 .

[11]  Laurence H. Pearl,et al.  A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone , 1997, Nature Structural Biology.

[12]  G. Mathis.  HTRF® Technology , 1999 .

[13]  P. Tsvetkov,et al.  Binding of ATP to Heat Shock Protein 90 , 2002, The Journal of Biological Chemistry.

[14]  Paul Workman,et al.  Overview: translating Hsp90 biology into Hsp90 drugs. , 2003, Current cancer drug targets.

[15]  J Fraser Glickman,et al.  A Comparison of ALPHAScreen, TR-FRET, and TRF as Assay Methods for FXR Nuclear Receptors , 2002, Journal of biomolecular screening.

[16]  Chrisostomos Prodromou,et al.  Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)‐domain co‐chaperones , 1999, The EMBO journal.

[17]  L. Neckers,et al.  Heat shock protein 90 , 2003, Current opinion in oncology.

[18]  Sreenath V. Sharma,et al.  Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol , 1998, Oncogene.

[19]  L. Whitesell,et al.  The stress response: implications for the clinical development of hsp90 inhibitors. , 2003, Current cancer drug targets.

[20]  N. Rosen,et al.  A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. , 2001, Chemistry & biology.

[21]  L. Neckers,et al.  Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  L. Pearl,et al.  Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.

[23]  Robert W. Bryant,et al.  Evaluation of Fluorescent Compound Interference in 4 Fluorescence Polarization Assays: 2 Kinases, 1 Protease, and 1 Phosphatase , 2003, Journal of biomolecular screening.